BÜHLMANN fCAL® ELISA News Archives - Buhlmann Diagnostics Corp

Category: BÜHLMANN fCAL® ELISA News

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s
Continue Reading